Rosen Law Firm announces a securities class action lawsuit against Medpace Holdings, Inc. for allegedly making false statements about backlog cancellation rates and providing misleading growth projections. Investors who purchased MEDP stock between April 22, 2025 and February 9, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is June 8, 2026.

A securities class action lawsuit has been filed against Medpace Holdings, Inc. alleging that defendants made false and misleading statements regarding the company's backlog cancellation rates. The lawsuit claims defendants misrepresented cancellation rates as 'well behaved' and provided overly positive growth expectations that could not be sustained. Investors with losses exceeding $100,000 are encouraged to join the class action before the June 8, 2026 lead plaintiff deadline.

Rosen Law Firm has filed class action lawsuits against Veritone, Inc., Medpace Holdings, Inc., and Stellantis N.V. on behalf of investors who suffered losses. Veritone is accused of inaccurately recording revenue and costs, overstating financial metrics, and maintaining deficient internal controls, leading to required financial restatements. Investors who purchased securities during specified class periods may be eligible for compensation.

Rosen Law Firm is soliciting investors who suffered losses in Medpace Holdings, Stellantis N.V., and Blaize Holdings to join securities class action lawsuits. The Medpace case alleges the company made false statements about backlog cancellation rates and provided misleading growth projections. The lead plaintiff deadline for Medpace is June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Rosen Law Firm is reminding investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 of the June 8, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, providing overly positive growth expectations that could not be sustained.

Rosen Law Firm is notifying investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 about a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, claiming they were 'well behaved' while concealing material adverse facts. Investors must move the court by June 8, 2026 to serve as lead plaintiff.

Rosen Law Firm is notifying investors about ongoing securities class action lawsuits against Regencell Bioscience Holdings Limited, Medpace Holdings, Inc., and Gossamer Bio, Inc. The firm is seeking lead plaintiffs with a June 23, 2026 deadline. Investors who purchased securities during specified class periods may be eligible for compensation through contingency fee arrangements.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its financial performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations. The stock fell 15.9% on February 10, 2026, following the disclosure. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Rosen Law Firm is reminding investors in Lufax Holding Ltd, Medpace Holdings Inc., and Vital Farms Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false statements, lacked adequate internal controls, and had materially misstated financial results. Investors with losses exceeding $100K are encouraged to seek counsel before the May 20, 2026 deadline.

Rosen Law Firm is soliciting investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 to join a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, which were described as 'well behaved' when they were actually problematic, leading to investors suffering damages when the true details became public.